Become a Member

Track your favourite stocks
Create & monitor portfolios
Daily portfolio value

Company	Chg	Chg %
Quickpicks
£	%
Add shares to your quickpicks to display them here!

MaxCyte (MXCT) Share News

IN BRIEF: MaxCyte signs strategic platform license with Walking Fish

4th May 2023 17:26

MaxCyte Inc - cell-engineering technology platform based in US state of Maryland - Signs a strategic platform license with Walking Fish Therapeutics Inc, a biotechnology company that is "rapidly advancing B cell-based therapeutics." Under the terms of the agreement, Walking Fish obtains non-exclusive clinical and commercial rights to use MaxCyte's Flow Electroporation technology and ExPERT platform. In return, MaxCyte is entitled to receive platform licensing fees, clinical milestone payments and sales-based payments. Read More

UK earnings, trading statements calendar - next 7 days

3rd May 2023 14:50

IN BRIEF: MaxCyte Chair Richard Douglas buys USD350,000 in shares

30th Mar 2023 16:03

MaxCyte Inc - cell-engineering technology platform based in US state of Maryland - Non-Executive Chair Richard Douglas buys 80,000 shares at average USD4.32, worth USD345,480, on Wednesday. Now has 100,000 shares, a 0.1% stake. Read More

MaxCyte appoints new chief financial officer, effective immediately

28th Mar 2023 10:44

(Alliance News) - MaxCyte Inc on Tuesday said it appointed Douglas Swirsky as its new chief financial officer, effective immediately. Read More

MaxCyte revenue up as growth expected in 2023; net loss widens

16th Mar 2023 12:20

(Alliance News) - MaxCyte Inc on Thursday said revenue was up by a third in 2022, as it expects further growth in 2023. Read More

IN BRIEF: MaxCyte names members of new scientific advisory board

8th Mar 2023 18:14

MaxCyte Inc - Maryland, US-based cell-engineering focused company - Forms new scientific advisory board that will reflect on research in molecular design and cell engineering and gain an understanding of translational development, in order to leverage the benefits of impactful discoveries for therapeutic applications. Board will include scientists, Oliver Rando, Marcela Maus, Avery Posey and Nako Nakatsuka. Read More

UK earnings, trading statements calendar - next 7 days

8th Mar 2023 15:54

MaxCyte revenue grows in 2022, expects further revenue climb in 2023

7th Mar 2023 10:51

(Alliance News) - MaxCyte Inc on Tuesday announced a higher revenue for 2022, and said it anticipates revenue to grow further during 2023. Read More

TRADING UPDATES: DP Eurasia annual sales grow despite Russia decline

30th Jan 2023 16:23

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News: Read More

MaxCyte signs strategic platform licence with Catamaran Bio

4th Jan 2023 08:56

(Alliance News) - MaxCyte Inc on Wednesday said it signed a strategic platform licence with biotechnology company Catamaran Bio Inc. Read More

TRADING UPDATES: MaxCyte in deal; Angus to resume Saltfleetby drilling

5th Dec 2022 21:49

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News: Read More

UK earnings, trading statements calendar - next 7 days

2nd Nov 2022 15:43

TRADING UPDATES: LoopUp, Surface raise capital; MaxCyte wins deal

28th Sep 2022 21:38

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More

IN BRIEF: MaxCyte grows revenue but widens loss in second quarter

10th Aug 2022 22:01

MaxCyte Inc - Gaithersburg, Maryland-based platform for cell-based research - Says second quarter revenue grew 35% year-on-year to USD9.6 million from USD7.1 million, "driven by strong growth in the cell therapy market; core business revenues grew 45% led by revenue from cell therapy customers which increased 61%, with drug discovery revenues growing by 4%", the firm says. Net loss for the quarter widens to USD8.3 million from US4.4 million. For the first half as a whole, revenue rises 56% year-on-year to USD21.2 million from USD13.6 million, as net loss widens slightly to USD12.3 million from USD11.5 million. Expects core business revenue in full year to grow approximately 30%. Continues to expect SPL Program-related revenue to be around USD4 million for the year. Says is making investments to drive revenue growth, and expand applications for its technology. Read More

UK earnings, trading statements calendar - next 7 days

3rd Aug 2022 15:57

IN BRIEF: MaxCyte enters strategic platform license agreement with LG

12th Jul 2022 14:05

MaxCyte Inc - Gaithersburg, Maryland-based platform for cell-based research - Signs a strategic platform license agreement with Korean chemical company LG Chem Ltd, a subsidiary of LG Corp. Explains that the deal gives LG non-exclusive clinical and commercial rights to use MaxCyte's Flow Electroporation technology and ExPERT platform. MaxCyte will receive platform licensing fees and programme related revenue. Read More

UK shareholder meetings calendar - next 7 days

22nd Jun 2022 15:48

IN BRIEF: MaxCyte first-quarter loss narrows; raises annual guidance

10th May 2022 12:01

MaxCyte Inc - Gaithersburg, Maryland-based platform for cell-based research - Says is pleased with positive start to 2022 with "very strong" first-quarter results. For three months to March 31, posts net loss USD4.1 million, narrowed from USD7.1 million last year on revenue of USD11.6 million, up 78% from USD6.5 million. Generates total of USD2.0 million in Strategic Platform License program-related revenue in the first quarter of 2022, compared to immaterial SPL program-related revenue in the first quarter of 2021. For 2022, expects core business revenue to grow at least 25% compared to 2021 core business revenue. It also continues to expect SPL program-related revenue to be around USD4 million in 2022. Read More

TRADING UPDATES: BlueRock output rises; Watkin Jones profit to fall

13th Apr 2022 18:47

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More

MaxCyte widens net loss in 2021 while annual revenue increases

23rd Mar 2022 17:22

(Alliance News) - MaxCyte Inc on Wednesday posted a widened net loss of USD19.1 million in 2021, increased from a loss of USD11.8 million the year before. Read More

FTSE 100 Latest

Value8,275.66

Change0.00